PGAP2

Across TCGA pan-cancer cohorts, PGAP2 RNA is linked to patient survival in 21 of 34 cancer types, making it the most broadly survival-associated PGAP2 data layer compared with 3 for mutation status and 1 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher PGAP2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated PGAP2 expression acts as an unfavorable survival marker, although some lineages such as BRCA and LUSC show a favorable association.

LIHC, ACC, and BLCA are the cancer types where PGAP2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.706	0.841	<.001	69	view →
ACC	DFS	Median	All	0.269	0.634	<.001	67	view →
BLCA	DFS	Median	All	0.464	0.699	<.001	44	view →
KICH	DFS	Median	All	0.697	0.969	.002	42	view →
LGG	DFS	Median	All	0.780	0.882	<.001	42	view →
BRCA	DFS	Tertile	II,III,IV	0.932	0.865	.004	30	view →
COAD	DFS	Median	IV	0.259	0.657	.003	23	view →
KIRP	DFS	Tertile	All	0.758	0.927	.004	18	view →
LUSC	OS	Tertile	II,III,IV	0.559	0.300	.003	18	view →
HNSC	OS	Median	All	0.804	0.727	.023	14	view →
LUAD	OS	Median	All	0.782	0.877	.010	13	view →
KIRC	DFS	Quartile	All	0.744	0.490	.015	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 21 lineages.

PGAP2–LIHC (OS)

Open the LIHC breakdown →